1. Japan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
StemRIM Inc.

StemRIM Inc.

TTSE:4599
145.00
JPY
-5.00
(-3.33%)
19.64BMarket Cap
Dec 16Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
5.97
5.23
2.34
38.88
24.09
0.39
39.13
- -
- -
- -
- -
Basic EPS, GAAP
-2.46
-8.47
-16.85
6.44
-10.02
-32.92
2.8
-32.98
- -
- -
- -
Free Cash Flow per Basic Share
-5.67
-6.83
-18.31
7.82
-10.48
-23.74
18.9
-30.76
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
22.38
42.28
58.62
191.06
181.76
158.33
170.35
144.57
- -
- -
131.29
Tangible Book Value per Share
22.38
42.28
58.59
191.04
181.73
158.31
170.34
144.53
- -
- -
131.26
Basic Weighted Avg Shares
50
38
43
54
58
59
60
61
62
62
62
Sales/Revenue/Turnover
300
200
100
2,100
1,400
23
2,350
- -
- -
- -
- -
Operating Margin (%)
-53.59
-187.57
-726.86
19.8
-42.41
-8,620.68
6.06
- -
- -
- -
- -
Depreciation Expense
1
1
2
8
44
49
48
44
- -
- -
- -
Net Income, GAAP
-124
-324
-721
348
-582
-1,948
168
-2,022
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
3.68
- -
- -
1.09
- -
- -
- -
- -
Profit Margin (%)
-41.31
-161.91
-721.21
16.56
-41.6
-8,479.75
7.16
- -
- -
- -
- -
Working Capital
992
1,871
2,593
10,612
10,410
9,191
10,223
8,810
- -
- -
8,054
LT Debt
- -
- -
10
7
4
1
- -
- -
- -
- -
- -
Total Equity
991
1,872
2,596
10,850
10,697
9,405
10,370
8,895
- -
- -
8,158
Return on Invested Capital (%)
- -
- -
- -
5.94
- -
- -
1.42
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
5.17
- -
- -
1.7
- -
- -
- -
- -
Return on Common Equity (%)
- -
-22.62
-32.28
5.17
-5.41
-19.38
1.7
-20.99
- -
- -
- -

Capital Structure

JPY

•

in mil. unless spec.
Apr'24
Jul'24
Jan'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
62
62
Market Capitalization
28,663
27,624
19,635

Working Capital

JPY

•

in mil. unless spec.
Apr'24
Jul'24
Jan'25
Total Current Assets
9,368
8,877
8,147
Cash, Cash Equivalents & STI
8,739
8,410
7,662
Accounts Receivable, Net
- -
- -
- -
Inventories
17
29
24
Total Current Liabilities
94
68
93
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-7.66
-8.79
-8.35
-8.18
-32.98
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Masatsune Okajima
Full Time Employees
45
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Saito Bio-Incubator Osaka OS Japan 567-0085
IPO Date
Aug 9, 2019
Website
stemrim.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
StemRIM Inc. (TSE: 4599) develops regeneration-inducing medicines that promote functional tissue regeneration for treating intractable diseases by mobilizing patients' endogenous stem cells to damaged tissues without cell transplantation; core pipeline products include Redasemtide (HMGB1 fragment peptide) for dystrophic epidermolysis bullosa, acute ischemic stroke, osteoarthritis of the knees, chronic liver disease, and psoriasis; autologous cell sampling devices; and stem cell gene therapy (SR-GT1) targeting curative treatment of dystrophic epidermolysis bullosa. The company, founded in 2006 and headquartered in Ibaraki City, Osaka, Japan, operates primarily in Japan with clinical trials extending to North America and collaborates with institutions such as Osaka University, Shionogi & Co., Ltd., and Shiseido Co., Ltd. on research and licensing agreements. Recent developments include patent registrations in October 2025 for SR-GT1 in Japan and Redasemtide's psoriasis indication in the US; issuance of new shares and stock acquisition rights as restricted stock remuneration and options to directors, employees, and collaborators in September-November 2025; presentation materials for business plan and growth potential in October 2025; and a global phase 2b trial of Redasemtide for acute ischemic stroke initiated in 2023.